02203nas a2200313   4500000000100000008004100001260001200042653004600054653004400100653002600144653001400170653004900184653002500233100001500258700001700273700001500290700001600305700001100321700001600332700001300348700001700361700001500378700001600393700001500409700001300424245012500437520131300562022001401875       2026                            d  c04/202610aangiotensin receptor-neprilysin inhibitor10aangiotensin-converting enzyme inhibitor10aChagas Cardiomyopathy10aenalapril10aheart failure with reduced ejection fraction10aSacubitril/valsartan1 aAlSejari N1 aGadelmawla A1 aAlfehaid A1 aAlMutairi O1 aTaqi M1 aAlibrahim A1 aAlOmar H1 aAlShammari M1 aAlharran A1 aAlsubaiei A1 aFrishman W1 aAronow W00aSacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure: A Systematic Review and Meta-Analysis3 a<p>Chagas cardiomyopathy represents a distinct and understudied etiology of heart failure with reduced ejection fraction (HFrEF). This meta-analysis aims to compare the efficacy and safety of sacubitril/valsartan versus enalapril in the treatment of patients with HFrEF due to Chagas cardiomyopathy with a total of 1225 patients (615 in the sacubitril/valsartan group and 610 in the enalapril group). There were no statistically significant differences between sacubitril/valsartan and enalapril in hospitalization for heart failure [risk ratios (RR) = 0.93; 95% confidence intervals (CI), 0.74-1.16; P = 0.53], cardiovascular mortality (RR = 0.91; 95% CI, 0.73-1.12; P = 0.37), or all-cause mortality (RR = 0.96; 95% CI, 0.79-1.17; P = 0.69). Heterogeneity was low across all efficacy outcomes (I2 = 0-4.1%). Similarly, we found no significant differences in safety outcomes, including symptomatic hypotension (RR = 1.14; 95% CI, 0.94-1.39), kidney dysfunction (RR = 1.08; 95% CI, 0.84-1.39), or hyperkalemia (RR = 1.26; 95% CI, 0.37-4.32). Our results indicated that sacubitril/valsartan has comparable efficacy to enalapril with no significant differences in hospitalization for heart failure, cardiovascular mortality, or all-cause mortality in patients with HFrEF secondary to Chagas cardiomyopathy.</p>  a1538-4683